SCHEDULE: Nantahala Capital Discloses 5.75% Stake in RAPT

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has disclosed a 5.75% beneficial ownership stake in RAPT Therapeutics, Inc.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack collectively reported beneficial ownership of 951,613 shares of RAPT Therapeutics, Inc. Common Stock.
• This ownership represents 5.75% of the total outstanding shares of RAPT Therapeutics, Inc. as of June 30, 2025.
• The reporting persons hold shared voting power and shared dispositive power over all 951,613 shares.
• Nantahala Capital Management, LLC is classified as an investment adviser, while Wilmot B. Harkey and Daniel Mack are identified as control persons of Nantahala.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the disclosure of a significant institutional stake, which can be interpreted as a vote of confidence in the company, although the filing itself is purely factual.

Positives

• A significant institutional investor, Nantahala Capital Management, has taken a notable stake in RAPT Therapeutics, which may signal confidence in the company's future prospects.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing indicates an institutional investment firm's interest in RAPT Therapeutics, a company in the biotechnology sector. Such disclosures are common and reflect ongoing portfolio adjustments by investment funds.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may be viewed positively, potentially increasing investor confidence and liquidity for RAPT Therapeutics' stock.

Key Dates

Keywords

RAPT Therapeutics, Nantahala Capital Management, Beneficial Ownership, SEC Filing, Schedule 13G, Institutional Investment, Biotechnology, Common Stock